CA9 and renal carcinoma: Sunitinib, an inhibitor of multi-tyrosine kinase, has been shown to upregulate the expression of carbonic anhydrase IX (CAIX) and enhanced the efficacy of anti-CAIX CAR T cells against renal cancer [256].